The Strategy And Business Of Engineered Blood Substitutes

Main Category: Blood / Hematology
Article Date: 10 Jun 2008 - 3:00 PDT

email to a friend   printer friendly   opinions  

Transfusions of whole blood and blood components represent one of the most widely used life-saving procedures in the healthcare sector. But the complexities of human blood including the risks of transmitting blood borne diseases and the uncertainty of adequate factor-matched supplies have long been the Achilles heel of a system that relies on blood donations for transfusions and blood product therapeutics.

A number of companies are working toward the commercialization of blood substitutes that are designed to eliminate most of the shortcomings of blood transfusions while creating an alternative product for a world market valued at around $9 billion annually.

Over the years, the path to commercialization has seen many hopeful product candidates fall by the wayside, and for the new generation of candidates several hurdles remain. Beyond clinical endpoints, factors such as cost relative to donated blood and managed care acceptance also await. Successful participants will be those companies able to endure the lengthy development cycle while creating commercial avenues through partnerships with established sector companies.

These findings are contained in a new report: Blood Substitutes: the Next Generation.

More information is available at http://www.greystoneassociates.org.

About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

Greystone Associates

• Additional
• References
• Citations